Oligonucleotide-Based Proteolysis Targeting Chimeras for STAT3 Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pharmacological inhibition of oncogenic and immunoregulatory transcription factors, such as STAT3, is challenging and requires alternative strategies.
Innovation Solution
Development of oligonucleotide-based proteolysis targeting chimeras (PTCs) that covalently bind to transcription factor binding sites and ubiquitin ligases, facilitating the degradation of target proteins like STAT3 through the ubiquitin-proteasome pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional pharmacological inhibition methods are used to target transcription factors like STAT3, then the approach is straightforward, but it fails to achieve effective inhibition because these transcription factors lack enzymatic activity
Solution Approach 1:
The patent introduces an intermediary mechanism (ubiquitin-proteasome pathway) to achieve degradation of non-enzymatic transcription factors. The PTC compound acts as a mediator that bridges the transcription factor binding site and ubiquitin ligase, enabling targeted protein degradation without requiring enzymatic activity in the target transcription factor
Solution Approach 2:
The invention changes the parameter of target protein fate from simple inhibition to active degradation. By designing compounds that recruit ubiquitin ligases to transcription factor binding sites, the system transforms the outcome from blocking activity to complete protein breakdown, overcoming the limitation of non-enzymatic targets
2Reliability
If oligonucleotide-based PTC compounds are designed to bind both transcription factor binding sites and ubiquitin ligases, then targeted degradation of STAT3 is achieved, but the molecular complexity of the compound increases
Solution Approach 1:
The patent merges multiple functional elements into a single oligonucleotide-based PTC compound: the transcription factor binding sequence, the ubiquitin ligase binding moiety, and the covalent linker connecting them. This consolidation achieves targeted degradation while managing complexity through integrated design
Solution Approach 2:
The PTC compound functions as a composite molecular structure combining nucleic acid sequences with ubiquitin ligase binding compounds. This composite approach enables simultaneous interaction with multiple biological targets (transcription factor binding site and ubiquitin ligase) through a single multifunctional molecule
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the degradation of STAT3 protein, offering potential therapeutic benefits for cancer, autoimmune disorders, and neurodegenerative diseases by specifically targeting and reducing STAT3 levels.
Implementation Method 1
a first nucleic acid sequence capable of binding to a transcription factor binding site
Implementation Method 2
a ubiquitin ligase binding compound (i.e., a monovalent compound capable of binding a ubiquitin ligase protein) covalently bound to the first nucleic acid
Implementation Method 3
facilitating the degradation of target proteins like STAT3 through the ubiquitin-proteasome pathway
Data Source
AI summary
Compounds and pharmaceutical compositions useful to treat cancer (e.g., lymphoma), neurodegenerative diseases, and autoimmune disorders include (1) a first nucleic acid sequence capable of binding to a transcription factor, for example, a signal transducer and activator of transcription (STAT) factor, such as STAT3, (2) a second nucleic acid sequence capable of binding a Toll-like receptor protein, for example, a CpG oligodeoxynucleotide, and (3) a ubiquitin ligase binding compound capable of binding a ubiquitin ligase protein, for example, a compound that is capable of binding a cereblon protein, such as lenalidomide, pomalidomide, or thalidomide.